Brad Margus leads Cerevance, a clinical-stage drug development company he cofounded to advance new therapeutics for brain diseases. The company has raised $94 million from Google Ventures, Bill Gates, Casdin Capital, Lightstone Ventures, Takeda Ventures, Foresite Capital, UPMC Enterprises, Dolby Ventures and the Dementia Discovery Fund. In 2013, Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic data. From 2009 to 2012, as co-founder and CEO of Envoy Therapeutics, Margus led the discovery of therapeutics for brain diseases and then sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Margus was co-founder and CEO of Perlegen Sciences, a leader in analyzing genetic variation that raised $257 million and partnered with global pharmaceutical companies.
.svg)
